NEW YORK (GenomeWeb News) – Toronto-based MDS said today that it has completed the divestiture of its Phase II-IV Pharma Services operations to INC Research, a contract research organization based in Raleigh, NC.

Under the terms of the agreement, INC Research has acquired MDS Pharma Services' Phase II-IV operations, which includes approximately 800 employees who conduct clinical trials in more than 25 countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.